BR112015024516A2 - métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação - Google Patents

métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação

Info

Publication number
BR112015024516A2
BR112015024516A2 BR112015024516A BR112015024516A BR112015024516A2 BR 112015024516 A2 BR112015024516 A2 BR 112015024516A2 BR 112015024516 A BR112015024516 A BR 112015024516A BR 112015024516 A BR112015024516 A BR 112015024516A BR 112015024516 A2 BR112015024516 A2 BR 112015024516A2
Authority
BR
Brazil
Prior art keywords
methods
costimulation
block
risk
rejection
Prior art date
Application number
BR112015024516A
Other languages
English (en)
Inventor
D Kirk Allan
Rae Espinosa Jaclyn
M Townsend Robert
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112015024516A2 publication Critical patent/BR112015024516A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Prostheses (AREA)

Abstract

resumo patente de invenção: "métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação". a presente invenção refere-se a métodos que utilizam alterações nos níveis de células t cd4+cd57+ para determinar a susceptibilidade de um paciente transplantado ou paciente que necessite dele para rejeição resistente ao bloqueio de coestimulação. estes métodos são úteis para identificar regimes de medicamentos eficazes para o tratamento de desordens imunológicas associadas com o transplante de enxerto e/ou a manutenção de um transplante.
BR112015024516A 2013-03-28 2014-03-27 métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação BR112015024516A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361806206P 2013-03-28 2013-03-28
PCT/US2014/031945 WO2014160822A1 (en) 2013-03-28 2014-03-27 Methods for identifying patients at risk for costimulation blockade resistant rejection

Publications (1)

Publication Number Publication Date
BR112015024516A2 true BR112015024516A2 (pt) 2017-10-24

Family

ID=50686197

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015024516A BR112015024516A2 (pt) 2013-03-28 2014-03-27 métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação

Country Status (12)

Country Link
US (4) US20160153990A1 (pt)
EP (1) EP2981825A1 (pt)
JP (1) JP2016515706A (pt)
KR (1) KR20150137087A (pt)
AU (1) AU2014241195A1 (pt)
BR (1) BR112015024516A2 (pt)
CA (1) CA2908272A1 (pt)
EA (1) EA201591883A1 (pt)
HK (1) HK1220766A1 (pt)
MX (1) MX2015013507A (pt)
SG (1) SG11201506919XA (pt)
WO (1) WO2014160822A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201418896D0 (en) * 2014-10-23 2014-12-10 Isis Innovation Biomarker and therapy intervention for malignancy risk patients
JP6749593B2 (ja) * 2017-03-10 2020-09-02 国立大学法人横浜国立大学 モノクローナル抗体の製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002360A1 (en) 1991-07-16 1993-02-04 Transmed Biotech Incorporated Methods and compositions for simultaneous analysis of multiple analytes
DE60225914T2 (de) * 2001-05-23 2009-07-23 Bristol-Myers Squibb Co. Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
CA2603970A1 (en) * 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules

Also Published As

Publication number Publication date
MX2015013507A (es) 2016-01-14
CA2908272A1 (en) 2014-10-02
EA201591883A1 (ru) 2016-02-29
US20200072838A1 (en) 2020-03-05
US20170328903A1 (en) 2017-11-16
EP2981825A1 (en) 2016-02-10
KR20150137087A (ko) 2015-12-08
AU2014241195A1 (en) 2015-11-12
US20220334112A1 (en) 2022-10-20
WO2014160822A1 (en) 2014-10-02
US11385228B2 (en) 2022-07-12
SG11201506919XA (en) 2015-10-29
HK1220766A1 (zh) 2017-05-12
US10488413B2 (en) 2019-11-26
JP2016515706A (ja) 2016-05-30
US20160153990A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
MX2021014047A (es) Metodos de diagnostico para tratamiento con linfocitos t.
MA52909A (fr) Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
PH12018502577B1 (en) Slit-robo signaling for diagnosis and treatment of kidney diseases
MA38308B1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
MX2017006242A (es) Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas.
EA201691314A1 (ru) Терапевтические способы и композиции
BR112016016525A2 (pt) Método para indução de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+ em um indivíduo, método para melhorar uma condição em um indivíduo, e método para a produção de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MD3593808T2 (ro) Polimeri de legare a protonilor pentru administrare orală
MX2019005299A (es) Anticuerpos anti-receptor del factor de crecimiento de tipo insulinico humano 1 (anti-igf-1r) con abolicion de la union al fcrn y su uso en el tratamiento de enfermedades oculares vasculares.
BR112015022473A2 (pt) método e sistema para prever a resposta a tratamentos contra a dor
BR112013029501A2 (pt) indução de tolerância imune usando metotrexato
BR112016028918A2 (pt) tratamento de hipertrigliceridemia grave
BR112017004729A2 (pt) processo de tratamento de doenças causadas por metástase óssea, medicamentos para as mesmas e processo de previsão do resultado clínico de tratamento de doenças causadas por metástase óssea
BR112015030099A2 (pt) marcador para desordens de esfingomielinase ácida e usos do mesmo
BR112015024516A2 (pt) métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
BR112015017815A2 (pt) método para prever o início dos sintomas extrapiramidais (eps) induzidos por um tratamento a base de antipsicótico
Pinto et al. Hypertension and adherence to the therapeutic regímen in primary health care

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2507 DE 22-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.